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In recent years, increasing attention has fo-
cused on HIV-1–specifi  c CD4+ T lympho-
cytes, which are thought to play a central role 
in initiating and maintaining antiviral immu-
nity and may be critical for control of HIV-1 
replication (1). Several reports have suggested 
that control of HIV viremia is associated with 
robust HIV-specifi  c CD4+ T cell proliferative 
responses. Long-term nonprogressors with low 
virus loads have higher levels of HIV-specifi  c 
CD4+ T cell proliferative responses compared 
with those of HIV-1–infected subjects with 
progressive disease (2, 3), and similar results 
have been reported in untreated patients with 
chronic HIV-1 infection (4). Studies in HIV-
exposed but seronegative individuals also sug-
gest that HIV-specifi  c CD4+ T cell responses 
may be associated with a reduced risk of HIV 
infection (5). However, other reports have 
identifi  ed HIV-specifi  c CD4+ T cell responses 
in subjects with progressive disease but have 
not observed a signifi  cant relationship between 
the magnitude of these responses and control 
of viremia (6, 7). Therefore, the signifi  cance of 
virus-specifi  c CD4+ T cell responses in HIV-1 
infection and the factors contributing to pro-
gression to AIDS remain unclear. Moreover, 
HIV-specifi  c CD4+ T cells are preferentially 
infected by HIV and, in the context of struc-
tured treatment interruptions, may serve as 
a reservoir for ongoing HIV replication (8). 
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We investigated simian immunodefi  ciency virus (SIV)-specifi  c CD4+ T cell responses in 
rhesus macaques chronically infected with attenuated or pathogenic SIV strains. Analysis of 
SIV∆nef-infected animals revealed a relatively high frequency of SIV-specifi  c CD4+ T cells 
representing 4–10% of all CD4+ T lymphocytes directed against multiple SIV proteins. Gag-
specifi  c CD4+ T cells in wild-type SIV-infected animals were 5–10-fold lower in frequency 
and inversely correlated with the level of plasma viremia. SIV-specifi  c CD4+ cells from 
SIV∆nef animals were predominantly CD27−CD28−CD45RAlowCCR7−CCR5−, consistent with 
an effector–memory subset, and included a fully differentiated CD45RA+CCR7− subpopula-
tion. In contrast, SIV-specifi  c CD4+ T cells from SIV-infected animals were mostly CD27+C
D28+CD45RA−CCR7+CCR5+, consistent with an early central memory phenotype. The 
CD45RA+CCR7−CD4+ subset from SIV∆nef animals was highly enriched for effector CD4+ 
T cells, as indicated by the perforin expression and up-regulation of the lysosomal mem-
brane protein CD107a after SIV Gag stimulation. SIV-specifi  c CD4+ T cells in attenuated 
SIV-infected animals were increased in frequency in bronchioalveolar lavage and decreased 
in lymph nodes, consistent with an effector–memory T cell population. The ability of 
SIV∆nef to induce a high frequency virus-specifi  c CD4+ T cell response with direct effector 
function may play a key role in protective immunity produced by vaccination with attenu-
ated SIV strains.
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Although emerging data indicate a signifi  cant role for both 
CD4+ and CD8+ T lymphocytes in determining viral set 
point in HIV-1 infection (9), it is diffi   cult to draw defi  nitive 
conclusions from these studies.
The dramatic ability of live attenuated mutants of simian 
immunodefi  ciency virus (SIV) to induce protection against 
subsequent challenge with pathogenic strains of SIV (10–13) 
has provided a valuable model to examine potential mecha-
nisms responsible for protective immunity (14). Several stud-
ies have demonstrated that animals vaccinated with live 
attenuated SIV develop neutralizing antibodies (10, 12), a 
relatively strong CTL response (15) associated with the pro-
duction of soluble antiviral factors (16) and the induction of 
a vigorous and sustained virus-specifi   c T helper response 
(17). However, the relative roles of each of these responses in 
protective immunity induced by live attenuated SIV remain 
poorly understood.
The objective of this study was to characterize in detail 
the phenotype and function of SIV-specifi  c CD4+ T cell 
  responses in rhesus macaques chronically infected with live 
attenuated or pathogenic SIV strains. Using optimized 
  conditions described previously for the detection of SIV-spe-
cifi  c CD4+ T lymphocytes (18), we examined the pheno-
type, cytokine expression, and functional characteristics of 
SIV-specifi  c CD4+ T cells from animals infected with atten-
uated SIV compared with wild-type SIV-infected animals. 
Our data demonstrate clear diff  erences in the maturation of 
SIV-specifi  c CD4+ T cell responses between macaques in-
fected with attenuated or pathogenic SIV strains. Macaques 
chronically infected with attenuated SIV had a relatively high 
frequency virus-specifi  c CD4+ T cell response with an eff  ec-
tor–memory phenotype, whereas monkeys chronically in-
fected with wild-type SIV had a low frequency response with 
a less mature phenotype. Moreover, a subset of SIV-specifi  c 
CD4+ T cells in attenuated virus-infected animals possessed 
the potential for direct eff  ector function, as indicated by the 
up-regulation of the lysosomal membrane protein CD107a 
and the presence of perforin.
RESULTS
Detection of high frequency SIV Gag-specifi  c CD4+ 
T lymphocyte responses in rhesus macaques with chronic 
attenuated SIV infection
Our initial studies focused on rhesus macaques that had been 
chronically infected for 13–15 yr with attenuated SIV∆nef 
(Table S1, available at http://www.jem.org/cgi/content/
full/jem.20060134/DC1) and had previously been shown to 
have strong SIV-specifi  c CD4+ T cell proliferative responses 
(17). SIV-specifi  c CD4+ T cell responses were quantitated by 
intracellular cytokine staining (ICS) using a protocol opti-
mized for macaques (18). Representative responses of CD4+ 
T cells to stimulation with SIV Gag protein are shown in Fig. 
1 A. Using this assay, we found high frequencies of SIV p55 
Gag-specifi  c CD4+ T cells secreting TNF-α, IFN-γ or IL-2 
(mean = 6.7, 4.6, and 1.2%, respectively); however, no sig-
nifi   cant secretion of IL-4 or IL-10 was detected in any 
SIV∆nef-infected macaque (mean = 0.024%; Fig. 1 A). As 
expected, <0.03% of CD4+ T cells from SIV-seronegative 
uninfected macaques responded to SIV p55 with any of 
the cytokines tested (18 and not depicted). In all SIV∆nef-
  immunized animals, the frequency of SIV Gag-specifi  c CD4+ 
T cells secreting TNF-α or IFN-γ was four- to sixfold higher 
than the frequency of SIV Gag-specifi  c CD4+ T cells secret-
ing IL-2 (P ≤ 0.015; Fig. 1 B).
Correlation between the magnitude of SIV Gag-specifi  c 
CD4+ T cell responses and the degree of attenuation 
of the SIV strain
We next examined the relationship between the frequency of 
SIV Gag-specifi  c CD4+ T cell responses and the degree of 
attenuation of the SIV strains. Several diff  erent groups of ma-
caques were studied according to their SIV infection status, 
including animals chronically infected with live attenuated 
SIV∆nef (n = 5), SIV∆3 (n = 6), or SIV∆4 (n = 3) (listed in 
increasing order of the degree of attenuation; Table S1), and 
uninfected control animals (n = 6).
The frequency of CD4+ T lymphocytes expressing ei-
ther IFN-γ or TNF-α in response to Gag was highest in 
  animals immunized with SIV∆nef, with frequencies up to 
Figure 1.  Detection of SIV Gag-specifi  c CD4+ T cells in rhesus 
macaques immunized with SIV𝖫nef. (A) Representative ICS data for 
the analysis of cytokine production by CD3+CD4+ T cells from an 
SIV∆nef-immunized animal (71.88) after SIV p55 stimulation. The per-
centage of CD4+ T lymphocytes coexpressing CD69 and the appropriate 
intracellular cytokine is shown in the top right quadrant of each plot. 
These data are representative of results generated from fi  ve SIV∆nef-
infected macaques, each tested in at least 10 independent experiments. 
(B) The frequency of responding CD4+ T cells from SIV∆nef-infected ani-
mals after SIV p55 stimulation. p-values were determined by the non-
parametric Mann-Whitney U test. NS, not signifi  cant.JEM VOL. 203, November 27, 2006  2663
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8.2 and 10.1%, respectively (Fig. 2 A). Although the fre-
quency of TNF-α–secreting SIV-specifi  c CD4+ T lympho-
cytes exceeded the frequency of SIV-specifi  c IFN-γ–secreting 
CD4+ T lymphocytes in most animals, the production of 
both cytokines was highly correlated (R2 = 0.97; Fig. 2 B, 
right), and >65% of SIV-specifi  c TNF-α–secreting CD4+ 
T lymphocytes also coexpressed IFN-γ (Fig. 2 B, left, and 
not depicted). In addition, when we compared the frequen-
cies of SIV-specifi  c CD4+ T lymphocytes expressing IFN-γ 
and TNF-α induced by diff  erent strains of attenuated SIV, 
we found an inverse relationship between the degree of 
  attenuation of the SIV strains and the magnitude of SIV-
specifi  c CD4+ T lymphocyte responses (Mann-Whitney U 
test; P ≤ 0.025 for all comparisons between vaccinated 
groups; Fig. 2 A).
We also examined the frequency of SIV Gag-specifi  c 
CD4+ T cell responses in four SIV∆nef-immunized ma-
caques by the TNF-α ICS assay over a period of 5 yr. During 
this time, Gag-specifi  c CD4+ T cell responses were analyzed 
using cells stimulated with either recombinant p55 or over-
lapping peptide pools corresponding to the Gag protein. 
Although the observed frequency of Gag-specifi  c CD4+ T 
cells was slightly lower after stimulation with Gag peptides 
than with p55, the results of both were highly correlated 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20060134/DC1). Regardless of the mode of stimulation, 
we observed that the levels of Gag-specifi  c CD4+ T cells in 
all four ∆nef-infected animals slowly decayed over time (T1/2 = 
3.78 yr), despite consistently undetectable plasma viremia 
(SIV RNA < 120 copies/ml; Fig. 2 C, left) and normal 
CD4+ T cell counts (mean = 950/mm3; Fig. 2 C, right).
Breadth of SIV-specifi  c CD4+ T cell responses in macaques 
infected with SIV∆nef
To determine recognition of multiple SIV proteins by CD4+ 
T cells, PBMCs isolated from macaques infected with 
SIV∆nef were stimulated with overlapping peptide pools 
corresponding to the full sequence of SIVmac239 proteins 
(18). Signifi  cant TNF-α production in response to multiple 
SIV peptide pools was observed in peripheral blood CD4+ T 
lymphocytes from SIV∆nef-immunized animals (Fig. 3 A). 
High frequencies of CD4+ T cell responses to Gag were ob-
served in all SIV∆nef-immunized animals (Fig. 3 B) and 
ranged between 0.85 and 3.82% (mean ± S.D., 1.72 ± 
1.1%) of all CD4+ T lymphocytes. The dominant target pro-
teins for SIV-specifi  c CD4+ T lymphocytes from SIV∆nef-
vaccinated animals were Gag and Env (Fig. 3 B). Similar 
results were also found using PBMCs isolated from fi  ve ani-
mals infected with SIVmac∆3 (not depicted). However, in 
each ∆nef-vaccinated animal two to four additional SIV-
specifi  c peptide pools were found to elicit CD4+ T cell re-
sponses (generally Rev, Vif, Vpx, and Pol). Occasional low 
frequency CD4+ T cell responses to the Nef peptide pool 
(ranging from 0.09 to 0.15%) were observed in some 
SIV∆nef-immunized animals (Fig. 3 B). Epitope mapping of 
these CD4+ T cell responses demonstrated recognition of 
epitopes contained in the NH2-terminal 57 amino acids of 
Nef proximal to the deletion in SIV∆nef (unpublished data). 
The sum of all SIV-specifi  c CD4+ T cell responses in ∆nef-
vaccinated animals ranged from 2.8 to 6.4% and thus consti-
tuted a signifi  cant portion of all CD4+ T cells. Based on the 
immunodominance of the SIV Gag protein, as has been ob-
served for HIV-specifi  c CD4+ T cell responses in humans 
(19), our subsequent studies of SIV-specifi  c CD4+ T cell re-
sponses focused on Gag.
Detection of SIV Gag-specifi  c CD4+ T cell responses 
in rhesus macaques with wild-type SIV infection: 
association with plasma SIV RNA
To provide a point of reference for interpretation of our data on 
SIV-specifi  c CD4+ T cells in macaques chronically infected 
Figure 2.  The frequency of SIV Gag-specifi  c CD4+ T lymphocytes 
varies with the degree of attenuating of the vaccine strain and the 
time since immunization. (A) Percentage of Gag-specifi  c CD4+ T lym-
phocytes coexpressing CD69 and TNF-α (top left) or IFN-γ (top right). 
p-values were determined by the nonparametric Mann-Whitney U test. 
(B) Positive correlation between the percentage of SIV Gag-specifi  c CD4+ 
T lymphocytes secreting TNF-α or IFN-γ among individual animals. 
A representative dot plot gated on CD4+ T lymphocytes is shown (left; 
397.88). All percentages shown have had background staining of un-
stimulated PBMCs activity subtracted. (C) Longitudinal analysis of SIV 
Gag-specifi  c CD4+ T cell responses and absolute CD4+ T cell counts in 
four SIV∆nef-vaccinated macaques. SIV-specifi  c CD4+ T cell responses 
were evaluated after stimulation with SIV Gag p55 protein (fi  lled symbols) 
or SIV Gag15/11 peptide pool (open symbols). 2664  SIV-SPECIFIC EFFECTOR–MEMORY CD4+ T CELL RESPONSES | Gauduin et al.
with attenuated SIV strains, we also investigated responses in 
animals infected with wild-type SIVmac239 for 9–12 mo. 
Using our optimized ICS assay, we identifi  ed SIV Gag-
  specifi  c CD4+ T lymphocytes after stimulation with Gag 
peptides in most wild-type SIV-infected animals (Fig. 4 A, 
top) at frequencies ranging from 0.09 to 0.91% (mean = 
0.50 ± 0.41%; Fig. 4 B, left). However, when stratifi  ed 
  according to viral load, the frequency of Gag-specifi  c TNF-
α–expressing CD4+ T cells in animals with VL < 5 × 105 
copies/ml (mean = 0.58 ± 0.33%; n = 10) was signifi  cantly 
higher than in animals with VL > 5 × 105 copies/ml (mean = 
0.27 ± 0.16%; n = 12; P < 0.023). In comparison, the 
magnitude of SIV-specifi  c CD4+ T cells in SIVmac∆nef-
  immunized animals was signifi  cantly higher than in wild-type 
SIV-infected macaques with VL < 5 × 105 or VL > 5 × 105 
copies/ml in response to SIV Gag peptide pool stimulation 
(P < 0.0007 and P < 0.0001, respectively; Fig. 4 B, left). Similar 
results were found after stimulation with superantigen (Fig. 4 B, 
right), a fi  nding that may refl  ect the depletion of memory 
CD4+ T cells (and resulting enrichment of naive CD4+ T 
cells) in SIV-infected macaques (20) and the fact that naive 
CD4+ T cells produce substantially less TNF-α and IFN-γ 
after superantigen stimulation (21). However, depletion of 
memory CD4+ T cells in wild-type–infected macaques did 
not account for the progressive decrease in SIV-specifi  c CD4+ 
T cells in wild-type–infected animals shown in Fig. 4 B (left). 
A similar relationship was observed when the frequency of 
SIV-specifi  c CD4+ T cells was expressed as a percentage of 
memory CD4+ T cells (Fig. S2 A, available at http://www.
jem.org/cgi/content/full/jem.20060134/DC1).
We next investigated if the decreased frequency of SIV Gag-
specifi  c CD4+ T cells observed in wild-type SIV-infected 
Figure 3.  Breadth of SIV-specifi  c CD4+ T cell responses in SIV𝖫nef-
infected macaques. (A) Representative dot plots of SIV-specifi  c CD4+ 
T cell responses (macaque 71.88) to multiple SIV overlapping 15-mer pep-
tide pools corresponding to the full predicted sequence of the SIVmac239 
proteome. DMSO alone and the superantigen SEB served as negative and 
positive controls, respectively. All plots were gated on CD4+ T lymphocytes. 
(B) Responses to the indicated peptide pools are shown for each SIV∆nef-
infected animal. These data are representative of results of two indepen-
dent experiments for each of the fi  ve SIV∆nef-infected macaques studied.
Figure 4.  Cross-sectional analysis of the frequency of SIV Gag-
specific and CMV-specific CD4+ T lymphocytes in wild-type 
SIV-infected compared with SIVΔnef-infected macaques. (A) Repre-
sentative dot plots gated on CD4+ T lymphocytes from wild-type SIV-
  infected macaques with plasma viral RNA < 5 × 105 copies/ml (macaques 
244.99 and 327.98) or > 5 × 105 copies/ml (345.99 and 222.93) and com-
pared with PBMCs isolated from SIV∆nef-infected (71.88 and 267.87) ma-
caques. (B) Cross-sectional analysis of the frequency of SIV-specifi  c CD4+ T 
lymphocytes in SIV∆nef -infected and wild-type SIV-infected animals 
after SIV Gag15/11 peptide pool, rhesus CMV, or SEA plus SEB stimulation. 
p-  values were calculated by the nonparametric Mann-Whitney U test. NS, not 
signifi  cant. (C) Inverse correlation between the magnitude of SIV Gag-
specifi  c CD4+ T lymphocyte responses and plasma viremia in wild-type SIV-
infected animals (left). Correlation of total CD4+ T cell counts and plasma 
viral RNA in wild-type SIV-infected macaques with plasma SIV RNA < 5 × 105 
copies/ml (n = 7) and > 5 × 105 copies/ml (n = 12; right). Spearman 
rank correlation coeffi  cients (Rho) and p-values were calculated for all SIV-
infected macaques for plasma SIV RNA versus SIV Gag-specifi  c CD4+ T cell 
frequencies (Rho = −0.815; P = 0.0008), and for plasma SIV RNA versus 
absolute CD4+ T cell counts (Rho = −0.646; P = 0.0074). JEM VOL. 203, November 27, 2006  2665
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macaques with VL > 5 × 105 copies/ml was limited to SIV 
or refl  ected a generalized depletion of antigen-specifi  c CD4+ 
T lymphocytes. We therefore performed a cross-sectional 
analysis of CMV-specifi  c CD4+ T lymphocytes in a subset 
of SIV-infected animals that were CMV seropositive with 
plasma viral RNA > 5 × 105 copies/ml or < 5 × 105 cop-
ies/ml (Fig. 4 A, bottom). CMV-specifi  c CD4+ T lympho-
cytes were detected in all wild-type SIV-infected animals 
at frequencies ranging from 0.51 to 5.53% (1.87 ± 1.43%; 
n = 12; Fig. 4 B, right). However, no signifi  cant diff  erence in 
the frequency of CMV-specifi  c CD4+ T cell responses was 
observed between wild-type–infected animals with high and 
low viral loads (Fig. 4 B). Therefore, SIV-specifi  c but not 
CMV-specifi  c CD4+ T cell responses appear to be preferen-
tially lost during chronic SIV infection in rhesus macaques 
that have not yet progressed to clinical simian AIDS.
We next examined the relationship between the total SIV 
Gag-specifi  c CD4+ T cell frequency and plasma SIV RNA 
loads in wild-type SIV-infected macaques. Previous studies 
with HIV-infected patients suggested that there is an inverse 
correlation between HIV Gag-specifi  c CD4+ T cell responses 
and HIV viral load (2, 22). However, other studies were un-
able to detect a correlation between the frequency of re-
sponding HIV Gag-specifi  c CD4+ T cells and viral load 
(6, 7). We found a signifi  cant inverse relationship between the 
frequency of SIV-specifi  c CD4+ T cell responses and plasma 
viral RNA load for all SIV-infected animals (Rho = −0.81; 
P = 0.0008; Fig. 4 C, left). A similar relationship was ob-
served between the frequency of memory-corrected SIV-
specifi  c CD4+ T cells and plasma SIV RNA (Fig. S2 B). 
As has been observed in HIV-infected subjects (23), there 
was an inverse relationship between plasma viral RNA and 
Figure 5.  Phenotypic analysis of SIV-specifi  c CD4+ T lymphocytes 
in SIV∆nef- and wild-type SIV-infected macaques. Representative 
dot plots of TNF-α+–secreting CD4+ T cells from one SIV∆nef-immunized 
macaque (118.87) and one wild-type SIV-infected animal (104.98; 
VL < 5 × 105 copies/ml) are shown. All plots are gated on CD4+ cells 
after SIV Gag15/11 peptide pool stimulation (A) or SEB stimulation (B). The 
blue-colored population designates CD4+CD69+TNF-α+ cells, and the 
percentages are shown in the top dot plot. (C) Comparative analysis of 
SIV-specifi  c TNF-α–secreting CD4+ lymphocytes expressing the indicated 
phenotypic marker, including SIV∆nef-infected macaques (○; n = 6) and 
wild-type SIV-infected animals with plasma viral RNA < 5 × 105 copies/ml 
(●; n = 6). These results refl  ect data generated from three independent 
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absolute CD4+ T cell counts in wild-type SIV-infected ma-
caques (Fig. 4 C, right).
Phenotypic differences in SIV-specifi  c CD4+ T cells 
in macaques infected with attenuated or pathogenic 
SIV strains
Diff  erentiation of antigen-specifi  c CD4+ T cell responses can 
be tracked by analysis of cell surface molecules such as CD28, 
CD45RA, and CCR7 (24–26). We analyzed the expression 
of a panel of phenotypic markers on SIV-specifi  c CD4+ T 
cells defi   ned by ICS in rhesus macaques infected with 
SIV∆nef or SIVmac239. To ensure a suffi   cient population of 
SIV-specifi  c CD4+ T cells for comparative analysis, we focused 
our analysis on wild-type SIV-infected animals with plasma 
viral RNA < 5 × 105copies/ml, CD4 counts > 500/mm3, 
and no sign of disease progression for a period of 3 mo before 
and after our study (Table S2, available at http://www.jem.
org/cgi/content/full/jem.20060134/DC1).
As illustrated in Fig. 5 (A, left, and C), SIV-specifi  c CD4+ 
T lymphocytes from ∆nef-vaccinated animals were predom-
inantly CD27−/lowCD28−CCR5−CCR7− and largely β7 
  integrin−/low but CD95+ and CD11a+ with variable CD45RA 
expression, consistent with a late eff  ector–memory CD4+ 
T cell subset (Fig. 5 A, left). Repeated analysis of SIV∆nef-
infected animals for up to 2 yr revealed no signifi  cant change 
in the phenotype of these cells (not depicted). SIV-specifi  c 
CD4+ T lymphocytes from wild-type SIV-infected macaques, 
however, exhibited an intermediate memory phenotype that 
maintained expression of CD28 and CD27, were typically 
β7 integrin−/low and mostly CCR5+, but were CD45RA−/low 
with variable expression of CCR7 (Fig. 5, A, right, and 
C). Little to no diff  erence was seen for the expression of 
CD95 and CD11a because SIV-specifi  c CD4+ T lympho-
cytes in both animal groups were CD95+ and CD11a+ 
(Fig. 5, A and C). In contrast, staphylococcal enterotoxin 
B (SEB) stimulation elicited high frequency TNF-α produc-
tion by CD4+ T lymphocytes in SIV∆nef-vaccinated ani-
mals that were exclusively CD95+ but variable with respect 
to CD28, CD45RA, CCR5, and β7 integrin expression 
(Fig. 5 B).
A summary of the phenotype of SIV-specifi  c CD4+ T 
cells in ∆nef and wild-type SIV-infected macaques is pre-
sented in Fig. 5 C. These results clearly demonstrate that 
SIV-specifi  c CD4+ T cells exhibit a more fully diff  erenti-
ated eff  ector–memory phenotype during chronic infection 
with attenuated SIV∆nef compared with the early intermedi-
ate memory phenotype observed in chronic wild-type SIV-
mac239 infection.
Identifi  cation of SIV-specifi  c CD4+ T lymphocytes 
that degranulate in response to antigenic stimulation
Several recent reports have identifi   ed subsets of virus-
specifi  c CD4+ T cells with cytolytic function and provided 
evidence that this population of eff  ector CD4+ T cells may 
play a role in the control of viral infections, including HIV 
(27, 28). We therefore examined if SIV-specifi  c CD4+ T 
cells could degranulate in response to SIV-specifi  c   stimulation. 
By measuring the mobilization of cytolytic granule  membrane 
proteins (i.e., CD107a) to the cell surface (29), we were 
able to detect SIV-specifi  c CD4+ T cell degranulation by 
fl  ow cytometry.
We analyzed SIV-specifi  c  CD4+ T lymphocyte re-
sponses in SIV∆nef-infected animals by examining cell 
  surface expression of CD107a in conjunction with intracel-
lular TNF-α production after Gag peptide pool stimulation. 
Three distinct populations of SIV-specifi  c  CD4+ T cells 
in SIV∆nef-infected animals could be identifi  ed based on 
expression of CD107a and TNF-α. The majority of CD107a+ 
cells also expressed TNF-α, although a signifi  cant minority 
expressed CD107a alone (Fig. 6, A and B). Thus, a signifi  cant 
subpopulation of SIV-specifi  c CD4+ T cells in SIV∆nef-
  infected animals is able to degranulate in response to antigen-
specifi  c stimulation.
Perforin+ CD4+ T lymphocytes are a distinct subset 
of SIV-specifi  c cells during chronic infection 
with attenuated or pathogenic SIV strains
To further characterize the subset of SIV-specifi  c CD4+ T 
cells with direct eff  ector function, we also analyzed expres-
sion of perforin in CD4+ T lymphocytes. Analysis of unstim-
ulated CD4+ T lymphocytes from SIV∆nef-infected animals 
revealed a signifi  cant increase in the frequency of perforin-
expressing cells (14.6 ± 2.3%; n = 4), compared with normal 
(6.1 ± 2.0%) and SIV-infected animals (1.9 ± 1.1%; Fig. 7 A). 
Notably, after stimulation of lymphocytes from SIV∆nef or 
wild-type SIV-infected animals with SIV Gag peptides, the 
frequency of perforin-expressing CD4+ T cells decreased to 
negligible levels, accompanied by the expected increases in 
TNF-α or CD107a expression (Fig. 7 A), suggesting that the 
majority of perforin-expressing CD4+ T cells in SIV-infected 
animals was SIV specifi  c.
To more precisely characterize the subset of eff  ector 
CD4+ T cells, we analyzed perforin expression in conjunc-
tion with CD45RA and CCR7. Analysis of expression of 
single phenotypic markers on SIV-specifi  c  CD4+ T cells 
Figure 6.  Degranulation of SIV-specifi  c CD4+ T cells as assessed 
by up-regulation of the lysosomal membrane protein CD107a. 
(A) Representative dot plots of CD107a and TNF-α expression on CD4+ 
T lymphocytes after SIV Gag peptide pool stimulation in freshly isolated 
PBMCs from an SIV∆nef -infected macaque (118.87). The right panel is 
gated on CD4+ T cells. (B) Distribution of CD107a and TNF-α expression 
on SIV-specifi  c CD4+ T cells from SIV∆nef-infected animals.JEM VOL. 203, November 27, 2006  2667
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described in Fig. 5 suggested that the majority of SIV-
  specifi  c CD4+ T cells in SIV∆nef-infected animals was 
either CCR7−CD45RA− or CCR7−CD45RA+, a conclu-
sion confi  rmed by ICS assays conducted with simultaneous 
analysis of both markers (Fig. 7 B). We therefore analyzed 
perforin expression in subsets of CD4+ T cells defi  ned by 
CCR7 and CD45RA expression before and after SIV stimu-
lation. The relatively high levels of perforin expression in 
CCR7−CD45RA− and CCR7−CD45RA+ CD4+ T cells 
(26 and 84%, respectively) declined precipitously after SIV-
specifi  c stimulation (compare the left with the right panels in 
Fig. 7 C). The decrease in perforin expression in these subsets 
was accompanied by an increase in CD107a expression, al-
though to a lesser extent (Fig. 7 D), again confi  rming the sig-
nifi  cant enrichment of CD4+ T cells with eff  ector function 
in the CCR7−CD45RA− and CCR7−CD45RA+ subsets in 
SIV∆nef-infected animals.
Preferential traffi  cking of SIV-specifi  c CD4+ T cells 
in attenuated SIV-infected animals to extralymphoid sites
Central memory T cells preferentially circulate to second-
ary lymphoid tissues, whereas eff  ector–memory T cells traf-
fi  c through extralymphoid tissues (24). To determine if the 
eff  ector–memory phenotype of SIV-specifi  c CD4+ T cells 
in attenuated SIV-infected animals predicted preferential lo-
calization of these cells to extralymphoid sites, we compared 
the frequency of SIV-specifi  c CD4+ T cells in peripheral 
blood, peripheral LNs, and bronchoalveolar lavage (BAL). 
The SIV Gag-specifi   c response was assessed by examina-
tion of CD107a and TNF-α expression in CD4+ T lym-
phocytes after Gag peptide pool stimulation (Fig. 8 A). The 
total SIV Gag-specifi  c response was calculated by combin-
ing the percentage of CD107+TNF-α−, CD107+TNF-α+, 
and CD107−TNF-α+ CD4+ T lymphocytes. As compared 
with peripheral blood, the average frequency of SIV-specifi  c 
CD4+ T lymphocytes was decreased eightfold in LNs and 
increased twofold in BAL from attenuated SIV-infected ma-
caques (Fig. 8 B). Correction of the frequency of SIV-specifi  c 
CD4+ T cells for the varying percentage of memory T cells 
in each of these compartments revealed a similar relation-
ship (Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20060134/DC1). Analysis of the range of eff  ector 
function of SIV-specifi  c CD4+ T cells in each of these sites 
revealed a signifi  cant increase in the percentage of TNF-α+ 
CD107a+ cells in peripheral blood, whereas LN and BAL 
exhibited an increased percentage of TNF-α− CD107a+ 
virus-specifi  c CD4+ T cells (Fig. 8 C). Thus, analysis of ex-
tralymphoid tissues revealed an enrichment of SIV-specifi  c 
CD4+ T cells as compared with LN or peripheral blood and 
a shift in the range of eff  ector functions.
DISCUSSION
CD4+ T cells are central to the development, interaction, 
and regulation of both antibodies and CD8+ T cell responses 
to viral infections (1); however, the relationship of virus-
specifi  c CD4+ T cell responses to control of HIV/SIV infec-
tion remains poorly understood. Eff  orts to understand the 
relationship between HIV-specifi  c CD4+ T cell responses 
and control of viremia in infected patients have led to dis-
crepant results (2, 6, 7, 22), in part due to the diff  erent tech-
niques used by these groups to quantitate virus-specifi  c T 
cell responses. Several factors inherent in the study of HIV-
infected subjects may confound the ability to determine the 
relationship between virus-specifi  c CD4+ T cell responses 
and viral suppression, including the heterogeneity of infect-
ing strains (leading to underrepresentation of type-specifi  c 
responses and uncertainty as to the replicative fi  tness of the 
HIV-1 strain infecting a given patient), as well as the eff  ects 
Figure 7.  Expression of perforin in subsets of CD4+ T lymphocytes 
from macaques infected with SIV𝖫nef or wild-type SIVmac239. 
(A) Expression of perforin (shown in black) in unstimulated and SIV Gag-
stimulated CD4+ lymphocytes (118.87 and 397.98). SIV-specifi  c CD4+ 
T cells identifi  ed on the basis of TNF-α secretion are displayed in blue. The 
total percentage of TNF-α–secreting CD4+ lymphocytes is shown. 
(B) Expression of CD45RA and CCR7 on SIV-specifi  c CD4+ lymphocytes. 
PBMCs from SIV∆nef- (118.87) or SIVmac239- (327.98) infected animals 
were stimulated with SIV Gag peptides, and antigen-specifi  c cells (shown 
in blue) were identifi  ed based on TNF-α secretion. The remaining CD4+ 
lymphocytes are displayed in red. (C) Loss of perforin expression in sub-
populations of CD4+ lymphocytes after SIV stimulation. (D) Up-regulation 
of CD107a in subpopulations of CD4+ lymphocytes after SIV Gag peptide 
stimulation. Data are representative of four uninfected (SIV−), four 
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of antiretroviral therapy. Studies in macaques infected with 
SIV can address many of these shortcomings, permitting 
analysis of immune responses using homologous sequences 
in animals infected with viruses of known and variable 
pathogenicity without the confounding eff  ects of antiretro-
viral therapy.
Our present fi  ndings confi  rm and extend our previous 
fi  ndings of relatively strong SIV-specifi  c CD4+ T cell re-
sponses in macaques vaccinated with live attenuated SIV 
strains (17). However, by the use of an optimized ICS tech-
nique (18) and examination of responses to all SIV proteins, 
we now show that this response is much higher than previ-
ously appreciated. The total magnitude of SIV-specifi  c CD4+ 
T cell responses can represent up to 4–10% of all CD4+ T 
cells. This high frequency response stands in contrast to that 
observed for many viruses such as mumps, infl  uenza, and 
vaccinia that are characterized by clearance of the infection 
(30–32). The magnitude of the virus-specifi  c CD4+ T cell 
response in SIV∆nef-infected animals is comparable to that 
observed in CMV-infected humans (32) and macaques (33), 
an observation that likely refl  ects ongoing low level antigenic 
stimulation in animals chronically infected with SIV∆nef de-
spite undetectable levels of plasma viremia. Although several 
of the attenuated SIV-infected macaques used in this study 
had been challenged with wild-type SIV, no diff  erence in the 
frequency or phenotype of SIV-specifi  c CD4+ T cells was 
observed between challenged and unchallenged animals (not 
depicted) and no evidence for wild-type SIV replication was 
evident at the time of study. The strength of the SIV-specifi  c 
CD4+ T cell response in ∆nef-infected animals is also re-
fl  ected by the breadth of the response, with an average of 
four diff  erent proteins recognized by each animal. The pres-
ence of a high frequency of virus-specifi  c CD4+ T cells in 
SIV∆nef-infected macaques is analogous to that reported in 
HIV-infected long-term nonprogressors (2, 34), although 
this fi  nding has not been confi  rmed by all groups (6) and is 
confounded by the eff   ects of viremia on proliferative re-
sponses in vitro (35). Several groups have failed to observe 
any signifi  cant correlation between the frequency of HIV-
specifi  c CD4+ T cell responses and control of viremia (6, 7). 
In contrast, we observed a clear, statistically signifi  cant in-
verse correlation between the magnitude of SIV Gag-specifi  c 
CD4+ T cell responses and plasma viremia in wild-type SIV-
infected animals, although we cannot determine whether 
SIV-specifi  c CD4+ T cell responses represent an indepen-
dent correlate of control of viremia or refl  ect an immune re-
sponse that is lost with increasing viral replication. Finally, 
SIV-specifi  c CD4+ T cell responses in ∆nef-infected animals 
were also distinguished by their ability to produce IL-2, 
whereas we observed no signifi  cant IL-2 production by SIV-
specifi  c CD4+ T cells from wild-type SIV-infected macaques 
(not depicted). These observations are consistent with those 
in HIV-infected patients that have shown that IL-2 produc-
tion by HIV-specifi  c CD4+ T cells is lost in the presence of 
ongoing viremia (36, 37).
Our data also provide insight into the maturation of HIV 
and SIV-specifi  c CD4+ T cell responses. As assessed by anal-
ysis of multiple specifi  c markers, SIV-specifi  c CD4+ T cells 
in macaques infected with attenuated SIV strains display a late 
eff  ector–memory phenotype, as demonstrated by the lack of 
expression of CD27, CD28, and CCR7, and by the presence of 
a subset of cells that are CCR7− and CD45RA+. Consistent 
with an eff   ector–memory phenotype, SIV-  specifi  c  CD4+ 
T cells in attenuated SIV-infected animals were increased in 
frequency in lung lavage and decreased in LNs as compared 
with peripheral blood. In contrast, SIV-specifi  c CD4+ T cell 
responses in wild-type SIV-infected animals displayed a less 
diff  erentiated central memory phenotype that maintained 
expression of CD27, CD28, and CCR7 but lacked expres-
sion of CD45RA. The relative immaturity of SIV-specifi  c 
CD4+ T cells appears similar to that previously reported in 
Figure 8.  Frequency and effector function of SIV-specifi  c CD4+ T 
lymphocytes in PBMCs, LNs, and lung lavage. (A) Representative dot 
plots of CD107a versus TNF-α expression on CD4+ T lymphocytes after 
SIV Gag peptide pool stimulation of lymphocytes from an SIV∆nef-
  infected animal (118.87). (B) Total SIV-specifi  c CD4+ T cells isolated from 
peripheral blood, LNs, and BALs from SIV∆nef- and SIV∆3-infected ma-
caques. The total Gag-specifi  c response was calculated by combining the 
percentage of CD107+TNF-α−, CD107+TNF-α+, and CD107−TNF-α+ CD4+ 
T lymphocytes. (C) Distribution of CD107a and TNF-α expression on SIV-
specifi  c CD4+ T cells isolated from various lymphoid and nonlymphoid 
compartments in attenuated SIV∆nef- (n = 4) and SIV∆3- (n = 3) in-
fected macaques. The decrease in the frequency of TNF-α+CD107a+ cells 
between PBMCs and LNs or BAL is signifi  cant (P < 0.05; Kruskall-Wallis 
with Dunn’s multiple comparisons test). JEM VOL. 203, November 27, 2006  2669
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an analysis of HIV-specifi  c  CD4+ T lymphocytes that 
  focused primarily on expression of CD27 and CD28 (25). 
Interestingly, SIV-specifi  c CD4+ T cells in wild-type SIV-
infected animals maintained expression of CCR5, suggesting 
that these cells would be readily susceptible to SIV infection, 
as has been reported for HIV-specifi  c CD4+ T cells (8). In 
contrast, SIV-specifi  c CD4+ T cells in SIV∆nef-vaccinated 
animals were CCR5−, suggesting that after pathogenic chal-
lenge these cells would be relatively resistant to SIV infection. 
Many factors may contribute to the apparent paradox of the 
phenotypic immaturity of SIV-specifi  c CD4+ T cells in wild-
type–infected animals that are chronically stimulated with 
large amounts of antigen. Direct infection of virus-  specifi  c 
CD4+ T cells, as previously reported for HIV (8), may play 
a dominant role. In this scenario, virus-specifi  c CD4+ T cells 
in wild-type–infected animals would die a premature death, 
whereas CD4+ T cell diff  erentiation would be allowed to 
proceed along a normal path in SIV∆nef-infected animals. 
Alternatively, defects in antigen presentation and costimula-
tion as well as adverse eff  ects of chronic high level antigenic 
stimulation may also play a role.
Interestingly, longitudinal analysis of Gag-specifi  c CD4+ 
T cell responses in four SIV∆nef-infected macaques over a 
fi  ve-year period showed a progressive decline. Whether this 
refl  ects selective loss of SIV-specifi  c CD4+ T cell responses, 
decreased antigenic stimulation, or a normal process of senes-
cence of antigen-specifi  c CD4+ T cell responses over ex-
tended periods of time is unknown. Slow declines in the 
frequency of virus-specifi  c CD4+ T cell responses have been 
reported for measles in humans (38) and lymphocytic chorio-
meningitis virus in mice (39), even when stable frequencies 
of virus-specifi  c CD8+ T cells have been observed.
Although CD4+ T lymphocytes have traditionally been 
viewed as helper cells that mediate their eff  ect on infectious 
pathogens through other lymphocyte populations, emerging 
evidence suggests that under certain conditions CD4+ T cells 
may mediate direct antiviral eff  ects. In murine models, evi-
dence for the ability of virus-specifi  c CD4+ T cells to directly 
suppress viral replication, either by cytokine secretion or di-
rect cytolysis, has been obtained for several viruses, including 
the γ-herpesvirus MHV-68 and Friend murine leukemia vi-
rus (40, 41). Expansion of perforin- or granzyme-expressing 
CD4+ T cells has been described in humans infected with 
HIV, EBV, or CMV (27, 28). Our data suggest that a signifi  -
cant subset of SIV-specifi  c CD4+ T cells in ∆nef-vaccinated 
animals is likely to possess direct cytolytic activity, as indi-
cated by their antigen-specifi  c up-regulation of the lysosomal 
membrane protein CD107a and loss of perforin expression. 
Additional evidence for the cytolytic activity of SIV-specifi  c 
CD4+ T cells comes from the observation that CD4+ T cell 
lines obtained by stimulation with an MHC class II–restricted 
peptide are able to lyse class II–expressing B cell lines sensi-
tized with the cognate peptide (unpublished data). In light of 
the ability of HIV and SIV to evade CD8+ T cell responses 
by Nef-mediated down-regulation of MHC class I molecules 
(42), generation of virus-specifi  c CD4+ T cells with cytolytic 
function may be particularly advantageous, especially in tar-
geting MHC class II–expressing reservoirs such as activated 
CD4+ T cells, macrophages, and dendritic cells.
The identifi  cation of a previously uncharacterized virus-
specifi   c immune response in SIV∆nef-vaccinated animals 
may have implications for our understanding of protective 
immunity induced by live attenuated SIV. Previous eff  orts to 
defi  ne mechanisms of immune protection mediated by live 
attenuated SIV strains have focused primarily on CD8+ T 
lymphocytes and neutralizing antibodies (11, 13, 43). Several 
of these studies have provided evidence for involvement of 
both CD8+ T lymphocyte responses and neutralizing anti-
body responses in protection mediated by attenuated SIV 
(12, 13, 43), but analysis of these responses alone does not 
appear to account for the substantial protection induced by 
SIV∆nef (11, 44). As noted above, the induction of virus-
specifi  c  CD4+ T cells with direct eff   ector function may 
preferentially emerge under conditions of chronic anti-
genic stimulation such as those provided by infection with 
SIV∆nef. As such, SIV-specifi  c CD4+ T cells with eff  ector 
function may represent a distinct feature of antiviral immune 
responses induced by live attenuated SIV infection that may 
play an important role in mediating immune protection. Ad-
ditional studies to defi  ne the kinetics of induction of this 
response after infection with SIV∆nef and to correlate this 
response with protection will be necessary to better under-
stand the role that eff  ector CD4+ T lymphocytes play in 
protective immunity.
MATERIALS AND METHODS
Animals. Animals were housed in the biocontainment facilities of the New 
England Primate Research Center (NEPRC) and were maintained in accor-
dance with the guidelines of the local institutional animal use committees 
and the Department of Health and Human Services (DHHS) Guide for the 
Care and Use of Laboratory Animals. 59 rhesus macaques were selected for 
this study, including animals infected with live attenuated SIV (n = 16; 
  Table S1), pathogenic SIV strains (n = 35; Table S2), and uninfected 
  macaques as negative controls (n = 8). Macaques vaccinated with attenuated 
SIV strains had been infected for 5–15 yr with SIVmac239∆nef (n = 7) (10), 
SIVmac239∆3 (n = 6) (45), or SIVmac239∆4 (n = 3) (45). A subset of these 
animals had been challenged 7–12 yr before our study with SIVmac239 or 
SIVmac251 but remained healthy without evidence of wild-type SIV infec-
tion or progression to simian AIDS. Selection criteria for wild-type SIV-
  infected macaques included chronic infection for 9–12 mo and no symptoms 
of simian AIDS for 3 mo before and after our analysis. When indicated, 
  animals were screened for naturally acquired CMV infection by testing sera 
for antibodies to rhesus CMV by ELISA, as described previously (33).
mAbs. mAbs were obtained from Becton Dickinson, Caltag Laboratories, 
DakoCytomation, or Immunotech and were conjugated with FITC, PE, 
peridinin chlorophyll protein, or allophycocyanin. A detailed list of specifi  c 
mAbs is provided in Table S3. Anti-CCR7 was used as a purifi  ed antibody, 
which was then bound with a biotin-conjugated rat anti–mouse IgM mAb 
(clone R6-60.2; BD Biosciences) and detected with streptavidin peridinin 
chlorophyll protein (BD Biosciences). CD28 and CD49d costimulation for 
ICS assays was performed as described previously (18).
Antigens and peptides. Antigens used for CD4+ T lymphocyte stimula-
tion included recombinant SIV p55 Gag protein derived from SIVmac239 and 
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consisted of 20-mer peptides overlapping by 10 amino acids corresponding 
to the SIVmac239 p55 Gag sequence and 15-mer peptides overlapping 
by 11 amino acids corresponding to the SIVmac239 Gag, Env, Tat, Rev, 
Nef, Vif, Vpr, Vpx, and Pol sequences. The Nef and Pol peptides were 
  obtained through the AIDS Research and Reference Reagent Program, 
  Division of AIDS, National Institute of Allergy and Infectious Diseases, 
  National Institutes of Health (NIH). All other peptides were synthesized by 
A. Khatri (Massachusetts General Hospital/Peptide Core Facility, Boston, 
MA). Peptides were reconstituted at 100 mg/ml in DMSO (Sigma-Aldrich) 
and combined in a pool such that each individual peptide was equally repre-
sented in the pool. For superantigen stimulation, staphylococcal enterotoxin 
A (SEA) and SEB were used together (100 ng/ml each; Sigma-Aldrich). 
Rhesus CMV antigen and control antigens were prepared as described 
  previously (33).
Cell processing and phenotypic analysis. Rhesus macaque PBMCs 
were isolated from heparinized venous blood and resuspended at 1.5–2.0 × 
106 cells/ml in RPMI 1640 medium (Invitrogen) supplemented with 10% 
FCS (Sigma-Aldrich), 10 mM Hepes, 2 mM L-glutamine, 50 U of penicillin 
per ml, and 50 μg of streptomycin per ml (R-10 medium). LN cells were 
isolated from minced LNs, and BAL was performed as described previously 
(20). Surface staining was performed as described previously (18). Data anal-
ysis was performed with CELLQuest (BD Biosciences) or PAINT-A-GATE 
Plus (BD Biosciences).
ICS analysis. Detection of antigen-specifi  c CD4+ T cells was performed as 
described previously using techniques optimized for rhesus macaque PBMCs 
(18, 33). In brief, fresh or thawed PBMCs, resuspended in complete R-10 
medium, were stimulated for 6 h at 37°C with the appropriate antigen in the 
presence of cross-linked costimulatory anti-CD28 and anti-CD49d as well 
as 10 μg/ml brefeldin A (Sigma-Aldrich) that was added for the last 4.5 h 
of stimulation (18). Stimulated cells were surface stained for 30 min at 4°C 
with anti-CD4 mAb and various combinations of mAbs to CD3, CD27, 
CD28, CD45RA, CD95, β7 integrin, CCR5, or CD107a. Cells were fi  xed 
and permeabilized with successive incubations in FACS Lysing and FACS 
Permeabilizing solutions (BD Biosciences) and incubated with anti-CD69 
and the appropriate anti-cytokine mAbs for 30 min at 4°C. PBMC aliquots 
unstimulated or stimulated with SEA and SEB for 6 h served as a nega-
tive and positive control, respectively. Positive controls for the detection 
of CD4+ T cell production of IL-4 and IL-10 included a 6–8-h stimulation 
with PMA/ionomycin and Con A, and ranged between 2 and 6%, respec-
tively (not depicted). 200,000 events were collected on a FACSCalibur (BD 
Biosciences), and the proportion of CD4+ or CD3+CD4+ T cells coexpress-
ing CD69 and the cytokine of interest were determined using CELLQuest 
or PAINT-A-GATE Plus. Gates for the determination of cytokine staining 
cells were established after stimulation with control antigen VSV-N or to 
yield <0.05% cytokine-expressing unstimulated cells. Where indicated, the 
memory-corrected frequency of SIV-specifi  c CD4+ cells was calculated by 
dividing the frequency of SIV-specifi  c CD4+ T cells by the fraction of mem-
ory CD4+ T cells determined at the same time point (6). The fraction of 
memory CD4+ T cells was calculated as the sum of the CD45RA−CCR7+, 
CD45RA+CCR7−, and CD45RA−CCR7− populations. Intracellular 
staining of perforin, granzyme A, and/or granzyme B versus cell surface 
markers was similar to cytokine analysis, except that permeabilization was 
performed in a 1× concentration of fi  xation/permeabilization solution 
  (Caltag Laboratories).
Plasma SIV RNA viral load measurements. Plasma SIV viral RNA 
levels were measured using a real-time RT PCR assay as described previ-
ously (46, 47).
Statistical analysis. Statistical analysis was performed using StatView (Abacus 
Concepts, Inc) and Instat (Graphpad Software, Inc.). Tests used included the 
Wilcoxon Signed Rank test, Spearman rank test, Mann-Whitney U test, and 
Kruskall-Wallis test with Dunn’s posttest analysis, as appropriate.
Online supplemental material. Table S1 shows the characteristics of at-
tenuated SIV-vaccinated rhesus macaques. Table S2 shows the characteristics 
of wild-type SIV-infected rhesus macaques, and Table S3 lists the mAbs used 
in these studies. Fig. S1 is an analysis of SIV Gag–specifi  c CD4+ T cell re-
sponses in SIV∆nef-vaccinated macaques using peptide pools. Fig. S2 is a 
cross-sectional analysis of the frequency of SIV Gag–specifi  c CD4+ memory 
T lymphocytes in SIV∆nef–infected and wild-type SIV-infected macaques. 
Fig. S3 shows the frequency of SIV-specifi  c CD4+ memory T lymphocytes 
in PBMCs, LNs, and lung lavages from SIV∆nef– and SIV∆3–infected ma-
caques. The online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20060134/DC1.
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